About: Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.33 (-5.67%)
ALT NASDAQ Altimmune Inc
Altimmune Inc share price
Atividade de preço de ALT
Último preço
$ 1,330
Variação (24h)
-0,08 USD (5,67%)
Volume
4.01M
Volume (média 4 sem.)
-
Abertura
$ 1,37
Variação do dia
$ 1,32 - $ 1,46
Fechamento anterior
$ 1,41
Último negócio
20 Nov, 9:00 pm GMT+0
Atrasado
20 Nov, 9:00 pm GMT+0
ALT price performance
Atrasado
20 Nov, 9:00 pm GMT+0
ALT details
quote.marketSignals